Quarterly ResultMay 14, 2026, 04:03 PM
International Stem Cell Q1 Net Loss $0.22M; Going Concern Warning
AI Summary
International Stem Cell Corporation reported a net loss of $220,000 for the first quarter of 2026, an improvement from a $256,000 net loss in the prior year. Product sales increased by 8.7% to $2.315 million. However, the company issued a going concern warning, citing historical net losses and insufficient cash to fund operations for at least twelve months without additional financing. The cash balance decreased to $933,000, and total liabilities increased to $5.049 million.
Key Highlights
- Company issued a going concern warning due to historical net losses and insufficient cash to sustain operations for 12 months.
- Net loss for Q1 2026 was $220,000, an improvement from $256,000 in Q1 2025.
- Product sales increased 8.7% to $2.315 million in Q1 2026 from $2.129 million in Q1 2025.
- Cash balance at March 31, 2026, was $933,000, down from $993,000 at December 31, 2025.
- Net cash provided by operating activities decreased to $121,000 in Q1 2026 from $227,000 in Q1 2025.
- Total liabilities increased to $5.049 million at March 31, 2026, from $4.579 million at December 31, 2025.
- Accumulated deficit reached $111.3 million as of March 31, 2026.
- One customer accounted for 57% of consolidated product sales in Q1 2026.